Announcements Trials
Browse Landscape

Phase

Phase 1 5Phase 2 2Phase 3 1Phase 1/2 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 2Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 4Myelodysplastic Syndromes 2Neoplasm, Residual 1Lung Neoplasms 1Leukemia, Myelomonocytic, Chronic 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

Cyclophosphamide 116fludarabine phosphate 101Busulfan 83Tacrolimus 75fludarabine 73Mycophenolic Acid 71Whole-Body Irradiation 65Peripheral Blood Stem Cell Transplantation 59Antilymphocyte Serum 58Cyclosporine 53Azacitidine 53Melphalan 50Cytarabine 47Filgrastim 43Methotrexate 41Granulocyte Colony-Stimulating Factor 34Decitabine 33Radiotherapy 28Thiotepa 27Cord Blood Stem Cell Transplantation 27thymoglobulin 26Stem Cell Transplantation 26Clofarabine 22Methylprednisolone 20Sirolimus 19Alemtuzumab 16venetoclax 15Specimen Handling 14sargramostim 13Etoposide 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Myelodysplastic Syndromes × pevonedistat × Clear all
NCT04712942 2023-08-21

Treatment of MDS/AML Patients With an Impending Hematological Relapse With AZA or ATA and Pevonedistat

University of Leipzig

Phase 2 Completed
14 enrolled
Myeloid

Myelodysplastic Syndromes, Neoplasm, Residual

NCT02610777 2022-09-19

An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML)

Takeda

Phase 2 Completed
120 enrolled 39 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡